Pirodavir, R-77975
4 – [2 - [1 - (6-Methyl-3-pyridazinyl)-4-piperidinyl] ethoxy] benzoic acid ethyl ester
ethyl 4-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}benzoate
ethyl 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]-ethoxy]benzoate
CAS REGISTRY NUMBER 124436-59-5
C21-H27-N3-O3
369.468
Janssen (Originator)
ANTIINFECTIVE THERAPY, Antiviral Drugs
Phase II
Pirodavir (R 77975) is the prototype of a novel class of broad-spectrum antipicornavirus compounds. Although its predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Whereas R 61837 was active almost exclusively against rhinovirus serotypes of antiviral group B, pirodavir is broad spectrum in that it is highly active against both group A and group B rhinovirus serotypes.
Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Susceptible rhinovirus serotypes were rendered noninfectious by direct contact with the antiviral compound. Their infectivity was not restored by dilution of virus-drug complexes, but was regained by organic solvent extraction of the compound for most serotypes.
Neutralized viruses became stabilized to acid and heat, strongly suggesting a direct interaction of the compounds with viral capsid proteins. Mutants resistant to R 61837 (up to 85 times the MIC) were shown to bear some cross-resistance (up to 23 times the MIC) to the new compound, indicating that pirodavir also binds into the hydrophobic pocket beneath the canyon floor of rhinoviruses.
Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication.
The mode of action appears to be serotype specific, since pirodavir was able to inhibit the adsorption of human rhinovirus 9 but not that of human rhinovirus 1A. Pirodavir is a novel capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes.
US 4992433
The condensation of 2-(1-benzylpiperidin-4-yl)ethanol (I) with 4-hydroxybenzoic acid ethyl ester (II) by means of triphenylphosphine and diazenedicarboxylic acid diethyl ester in THF gives 4-[2-(1-benzylpiperidin-4-yl)ethoxy]benzoic acid ethyl ester (III) as fumarate salt. This compound is debenzylated by hydrogenation with H2 over Pd/C in ethanol, yielding the free product (IV), which is finally condensed with 3-chloro-6-methylpyridazine (V) by means of K2CO3 in DMF.
Intermediate Name8-methoxy-2-methyl-4 (3H)-quinazolinone(I)
Spiro [indane-1, 4'-piperidine](II)
N-[Spiro [indane-1, 4'-piperidin]-1′-ylcarbonyl]-L-tryptophan benzyl ester(III)
N-[Spiro [indane-1, 4'-piperidin]-1′-ylcarbonyl]-L-tryptophan(IV)
(3S, 4R) -5 – [(1S) -1,2-dihydroxyethyl] -3,4-dihydroxydihydro-2 (3H)-furanone(V)
…………………………………
US4992433
B. Preparation of the Final Compounds EXAMPLE 25
A mixture of 10.4 parts of 3-chloro-6-methylpyridazine, 22.4 parts of ethyl 4-[2-(4-piperidinyl)ethoxy]benzoate butanedioate (1:1), 8.6 parts of sodium carbonate and 0.9 parts of N,N-dimethylformamide was stirred for 3 hours in an oil bath at .+-.150.degree. C. After cooling, water and dichloromethane were added and the layers were separated. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and ethanol (99:1 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2,2′-oxybispropane and 2-propanone (75:25 by volume). The precipitated product was filtered off and dried, yielding 17 parts (56.8%) of ethyl 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]-ethoxy]benzoate; mp. 130.1.degree. C. (comp. 1).
……………..
Journal of Medicinal Chemistry, 2003 , vol. 46, 15 p. 3181 – 3184
http://pubs.acs.org/doi/abs/10.1021/jm0202876
Scheme 1. Synthesis of Pirodavir (3) and Related Compounds
see mp and nmr data in supp file
http://pubs.acs.org/doi/suppl/10.1021/jm0202876/suppl_file/jm0202876_s.pdf
US2985657 *
Oct 12, 1959
May 23, 1961
Paul A J Janssen
1-(aroylalkyl)-4-heterocyclylpiperazines
US4068383 *
Sep 30, 1976
Jan 17, 1978
Hoechstmass Balzer Gmbh & Co.
Tape measure reel
US4451476 *
Oct 17, 1983
May 29, 1984
Sterling Drug Inc.
Isoxazoles as antiviral agents
US4604127 *
May 15, 1985
Aug 5, 1986
Eli Lilly And Company
Herbicidal pyridazinylimidazolidinone compounds
EP0137242A2 *
Aug 20, 1984
Apr 17, 1985
Sterling Winthrop Inc.
(Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof
EP0156433A2 *
Mar 15, 1985
Oct 2, 1985
Janssen Pharmaceutica N.V.
Anti-virally active pyridazinamines
EP0211457A2 *
Jul 9, 1986
Feb 25, 1987
Janssen Pharmaceutica N.V.
Novel (4-substituted-piperazinyl)pyridazines
JPS5877866A *
Title not available
read also
Antimicrobial Agents and Chemotherapy, 1995 , vol. 39, 2 p. 290 – 294
Filed under: Phase3 drugs, Uncategorized Tagged: PHASE 3, pirodavir